Efficiency and safety of plasma exchange in the treatment of severe COVID-19

Ochkin S.S.; Samoylov A.S.; Udalov Yu.D.; Kruglyakov N.M.; Bagzhanov G.I.

doi:https://doi.org/10.17116/anaesthesiology202104148

Ochkin S.S.

Burnazyan Federal Medical Biophysical Center of the FMBA of Russia

Samoylov A.S.

State Research Center — Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency

Udalov Yu.D.

State Research Center of the Russian Federation — Burnazyan Federal Medical Biophysical Center

Kruglyakov N.M.

State Research Center of the Russian Federation — Burnazyan Federal Medical Biophysical Center

Bagzhanov G.I.

State Research Center of the Russian Federation — Burnazyan Federal Medical Biophysical Center

Efficiency and safety of plasma exchange in the treatment of severe COVID-19

Authors:

Ochkin S.S., Samoylov A.S., Udalov Yu.D., Kruglyakov N.M., Bagzhanov G.I.

More about the authors

Journal: Russian Journal of Anesthesiology and Reanimatology. 2021;(4): 48‑53

DOI: 10.17116/anaesthesiology202104148

Read: 1818 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Ochkin SS, Samoylov AS, Udalov YuD, Kruglyakov NM, Bagzhanov GI. Efficiency and safety of plasma exchange in the treatment of severe COVID-19. Russian Journal of Anesthesiology and Reanimatology. 2021;(4):48‑53. (In Russ.)
https://doi.org/10.17116/anaesthesiology202104148

Использование инфографики авторами научных работ

Close metadata

OBJECTIVE

To study an efficacy and safety of therapeutic plasma exchange in the treatment of COVID-19.

MATERIAL AND METHODS

Efficacy and safety of plasma exchange in severe COVID-19 were retrospectively analyzed. Plasma exchange was performed within 24 hours after admission to ICU. Circulating plasma volume (70-150%) was replaced with donor fresh frozen plasma, CovRec plasma ≤300 ml and balanced crystalloid solutions ≤800 ml. Mean volume of exchange was 3000 ml (min 2000 ml, max 4000 ml). We analyzed mortality and need for mechanical ventilation in patients after plasma exchange in addition to standard therapy (main group) and in the control group (standard therapy alone).

RESULTS

Mortality in the main group was 16.67% (n=5), in the control group — 57.41% (n=31) (p=0.001).

CONCLUSION

Plasma exchange is an effective and safe method significantly reducing mortality in patients with severe COVID-19. These data are confirmed by laboratory data. A multiple-center study of efficacy and safety of plasma exchange in the treatment of severe COVID-19 is needed.

Keywords:

plasma exchange

COVID-19

cytokine storm

endotheliopathy

ARDS

coagulopathy

Authors:

Ochkin S.S.

Burnazyan Federal Medical Biophysical Center of the FMBA of Russia

Samoylov A.S.

State Research Center — Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency

Udalov Yu.D.

State Research Center of the Russian Federation — Burnazyan Federal Medical Biophysical Center

Kruglyakov N.M.

State Research Center of the Russian Federation — Burnazyan Federal Medical Biophysical Center

Bagzhanov G.I.

State Research Center of the Russian Federation — Burnazyan Federal Medical Biophysical Center

Received:

15.11.2020

Accepted:

17.12.2020

Close metadata

References:

Poston JT, Patel BK, Davis AM. Management of critically ill adults with COVID-19. JAMA. 2020;323(18):1839-1841. https://doi.org/10.1001/jama.2020.4914
Gralinski LE, Sheahan TP, Morrison TE, Menachery VD, Jensen K, Leist SR, Whitmore A, Heise MT, Baric RS. Complement activation contributes to severe acute respiratory syndrome coronavirus pathogenesis. MBio. 2018;9(5):e01753-18. https://doi.org/10.1128/mBio.01753-18
Yao XH, Li TY, He ZC, Ping YF, Liu HW, Yu SC, Mou HM, Wang LH, Zhang HR, Fu WJ, Luo T, Liu F, Guo QN, Chen C, Xiao HL, Guo HT, Lin S, Xiang DF, Shi Y, Pan GQ, Li QR, Huang X, Cui Y, Liu XZ, Tang W, Pan PF, Huang XQ, Ding YQ, Bian XW. A pathological report of three COVID-19 cases by minimally invasive autopsies. Zhonghua Bing Li Xue Za Zhi. Chinese Journal of Pathology. 2020;49(5):411-417. https://doi.org/10.3760/cma.j.cn112151-20200312-00193
Jin Y, Yang H, Ji W, Wu W, Chen S, Zhang W, Duan G. Virology, epidemiology, pathogenesis, and control of COVID-19. Viruses. 2020; 12(4):372. https://doi.org/10.3390/v12040372
Mei H, Hu Y. Characteristics, causes, diagnosis and treatment of coagulation dysfunction in patients with COVID-19. Zhonghua Xue Ye Xue Za Zhi. 2020;41(3):185-191. https://doi.org/10.3760/cma.j.issn.0253-2727.2020.0002
Chen C, Zhang XR, Ju ZY, He WF. Advances in the research of cytokine storm mechanism induced by Corona Virus Disease 2019 and the corresponding immunotherapies. Zhonghua Shao Shang Za Zhi. 2020;36(0):E005. https://doi.org/10.3760/cma.j.cn501120-20200224-00088
Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, Jin HJ, Tan KS, Wang DY, Yan Y. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak — an update on the status. Military Medical Research. 2020;7(11):11. https://doi.org/10.1186/s40779-020-00240-0
Quah P, Li A, Phua J. Mortality rates of patients with COVID-19 in the intensive care unit: a systematic review of the emerging literature. Critical Care. 2020;24(1):285. https://doi.org/10.1186/s13054-020-03006-1
McGonagle D, Sharif K, O’Regan A, Bridgewood C. The role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease. Autoimmunity Reviews. 2020;19(6):102537. https://doi.org/10.1016/J.AUTREV.2020.102537
Wang F, Nie J, Wang H, Zhao Q, Xiong Y, Deng L, Song S, Ma Z, Mo P, Zhang Y. Characteristics of peripheral lymphocyte subset alteration in COVID-19 pneumonia. The Journal of Infectious Diseases. 2020;221(11):1762-1769. https://doi.org/10.1093/infdis/jiaa150
Ravelli A, De Benedetti F, Viola S, Martini A. Macrophage activation syndrome in systemic juvenile rheumatoid arthritis successfully treated with cyclosporine. The Journal of Pediatrics. 1996;128(2):275-278. https://doi.org/10.1016/S0022-3476(96)70408-0
Davì S, Consolaro A, Guseinova D, Pistorio A, Ruperto N, Martini A, Cron RQ, Ravelli A; MAS Study Group. An international consensus survey of diagnostic criteria for macrophage activation syndrome in systemic juvenile idiopathic arthritis. The Journal of Rheumatology. 2011;38(4):764-768. https://doi.org/10.3899/jrheum.100996
De Benedetti F, Massa M, Robbioni P, Ravelli A, Burgio GR, Martini A. Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis. Arthritis and Rheumatism. 1991;34(9):1158-1163. https://doi.org/10.1002/art.1780340912
De Benedetti F, Brunner HI, Ruperto N, Kenwright A, Wright S, Calvo I, Cuttica R, Ravelli A, Schneider R, Woo P, Wouters C, Xavier R, Zemel L, Baildam E, Burgos-Vargas R, Dolezalova P, Garay SM, Merino R, Joos R, Grom A, Wulffraat N, Zuber Z, Zulian F, Lovell D, Martini A; PRINTO; PRCSG. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. The New England Journal of Medicine. 2012;367(25):2385-2395. https://doi.org/10.1056/NEJMoa1112802
Vastert SJ, Jamilloux Y, Quartier P, Ohlman S, Osterling Koskinen L, Kullenberg T, Franck-Larsson K, Fautrel B, de Benedetti F. Anakinra in children and adults with Still’s disease. Rheumatology. 2019;58(6):9-22. https://doi.org/10.1093/rheumatology/kez350
Quartier P, Allantaz F, Cimaz R, Pillet P, Messiaen C, Bardin C, Bossuyt X, Boutten A, Bienvenu J, Duquesne A, Richer O, Chaussabel D, Mogenet A, Banchereau J, Treluyer JM, Landais P, Pascual V. A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Annals of the Rheumatic Diseases. 2011;70(5):747-754. https://doi.org/10.1136/ard.2010.134254
Yokota S, Imagawa T, Mori M, Miyamae T, Aihara Y, Takei S, Iwata N, Umebayashi H, Murata T, Miyoshi M, Tomiita M, Nishimoto N, Kishimoto T. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet. 2008;371(9617):998-1006. https://doi.org/10.1016/S0140-6736(08)60454-7
Qanadli SD, Beigelman-Aubry C, Rotzinger DC. Vascular changes detected with thoracic CT in coronavirus disease (COVID-19) might be significant determinants for accurate diagnosis and optimal patient management. AJR. American Journal of Roentgenology. 2020;215(1):W15. https://doi.org/10.2214/AJR.20.23185
Mastellos DC, Ricklin D, Lambris JD. Clinical promise of next-generation complement therapeutics. Nature Reviews. Drug Discovery. 2019;18(9): 707-729. https://doi.org/10.1038/s41573-019-0031-6
Thompson BT, Chambers RC, Liu KD. Acute respiratory distress syndrome. The New England Journal of Medicine. 2017;377:562-572. https://doi.org/10.1056/NEJMra1608077
Gattinoni L, Coppola S, Cressoni M, Busana M, Rossi S, Chiumello D. Covid-19 does not lead to a “typical” acute respiratory distress syndrome. American Journal of Respiratory and Critical Care Medicine. 2020; 201(10):1299-1300. https://doi.org/10.1164/rccm.202003-0817le
Ciceri F, Beretta L, Scandroglio AM, Colombo S, Landoni G, Ruggeri A, Peccatori J, D’Angelo A, De Cobelli F, Rovere-Querini P, Tresoldi M, Dagna L, Zangrillo A. Microvascular COVID-19 lung vessels obstructive thromboinflammatory syndrome (MicroCLOTS): an atypical acute respiratory distress syndrome working hypothesis. Critical Care and Resuscitation. 2020;22(2):95-97.
Chang JC. Acute respiratory distress syndrome as an organ phenotype of vascular microthrombotic disease: based on hemostatic theory and endothelial molecular pathogenesis. Clinical and Applied Thrombosis/Hemostasis. 2019;25:1076029619887437. https://doi.org/10.1177/1076029619887437
Hill NS, Roberts K, Preston I. Pulmonary vasculopathy in acute respiratory distress syndrome: something new, something old. American Journal of Respiratory and Critical Care Medicine. 2010;182(9):1093-1094. https://doi.org/10.1164/rccm.201007-1116ED
Padmanabhan A, Connelly-Smith L, Aqui N, Balogun RA, Klingel R, Meyer E, Pham HP, Schneiderman J, Witt V, Wu Y, Zantek ND, Dunbar NM, Schwartz GEJ. Guidelines on the use of therapeutic apheresis in clinical practice — evidence-based approach from the Writing Committee of the American Society for Apheresis: the eighth special issue. Journal of Clinical Apheresis. 2019;34(3):171-354. https://doi.org/10.1002/jca.21705
Apheresis in the office setting. Journal of Oncology Practice. 2008;4(2):94-95. https://doi.org/10.1200/jop.0817002
Stahl K, Schmidt JJ, Seeliger B, Schmidt BMW, Welte T, Haller H, Hoeper MM, Budde U, Bode C, David S. Effect of therapeutic plasma exchange on endothelial activation and coagulation-related parameters in septic shock. Critical Care. 2020;24(1):71. https://doi.org/10.1186/s13054-020-2799-5